热毒宁注射液治疗新型冠状病毒肺炎的临床疗效分析

Clinical efficacy of Reduning injection in the treatment of novel coronavirus pneumonia

目的:探讨热毒宁注射液治疗新型冠状病毒肺炎的临床疗效。方法:本研究有效纳入新型冠状病毒肺炎患者77例,依据随机数字表法分为两组:治疗组36例,对照组41例。对照组给予西药常规治疗,治疗组在对照组基础上给予热毒宁注射液,治疗观察7 d;分别观察两组的体温、炎症指标、临床疗效。结果:治疗组患者从第3天开始平均体温达到正常范围内,且体温下降较对照组多,在第4天更为显著,两组比较差异有统计学意义(P=0.012);治疗组患者入院时IL-6水平显著高于对照组,差异有统计学意义(P=0.002),到第7天降到相同水平,其中从第3天开始降低更为显著。同样从第3天起,治疗组的外周血中性粒细胞数下降、淋巴细胞数升高、NLR下降明显,且NLR下降幅度明显优于对照组,差异有统计学意义(P=0.049);治疗组患者在第3天CURB-65评分明显低于对照组,两组比较差异有统计学意义(P=0.046);治疗组CURB-65评分≥3分的患者比例较对照组更少,且病情加重患者例数较对照组明显减少,差异有统计学意义(P=0.04);治疗组呼吸衰竭(P=0.05)以及转入ICU(P=0.04)的患者例数比例也较对照组明显减少;治疗组的住院天数(P=0.014)、住院费用(P=0.013)以及核酸转阴时间(P=0.024)均明显低于对照组,均差异有统计学意义。结论:热毒宁注射液联合西药常规治疗可提高新型冠状病毒肺炎的临床疗效,在降低体温、缩短发热时间及控制炎症反应、恢复患者免疫水平方面具有优势。

Objective:To investigate the clinical efficacy of Reduning injection in the treatment of novel coronavirus pneumonia.Methods:Seventy-seven subjects of corona virus disease 2019(COVID-19)were effectively included in the study,and were divided into groups according to a random number table method.The treatment group consisted of 36 patients,and the control group consisted of 41 patients.The control group received conventional treatment with Western medicine,while the treatment group received injections of Reduning on top of the control group's treatment.The treatment was observed for 7 days.The body temperature,inflammatory indicators,and clinical efficacy of the two groups were observed.Results:The average body temperature of the patients who used Reduning injection from the third day reached the normal range,and the body temperature dropped more than that of the control group,especially on the fourth day(P=0.012).The level of IL-6 in the treatment group at admission was significantly higher than that in the control group(P=0.o02),and decreased to the same level on the seventh day,with the decrease being more significant since the third day.Similarly,after the third day,the number of neutrophils and lymphocytes in the peripheral blood of the treatment group decreased significantly,while the number of lymphocytes and NLR decreased significantly,and the decline in NLR was significantly obvious than that of the control group(P=0.049).The treatment group had significantly lower CURB-65 score on the third day than the control group(P=0.046),and the proportion of patients with CURB-65 score≥3 was less than that in the control group,and the number of patients with exacerbation was significantly reduced compared with the control group(P=0.04),among which the number and proportion of patients with respiratory failure(P=0.05)and admission to the ICU(P=0.04)were also significantly reduced compared with the control group.The hospitalization days(P=0.014),hospitalization expenses(P=0.013),and nucleic acid negative time(P=O.024)of the treatment group were significantly lower than those of the control group.Conclusion:Reduning injection combined with routine Western medicine treatment can improve the clinical efficacy of COVID-19,and has advantages in lowering body temperature,shortening fever time,controlling inflammatory reaction,and restoring the immune level of patients.